HC Wainwright & Co. Assumes Liquidia at Buy, Announces Price Target of $76
HC Wainwright & Co. analyst Matthew Caufield assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $76.
Last updated: 2026-11-19 04:53:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Liquidia Corporation (LQDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $56.43, with a market capitalization of $5.08B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.31 to $93.61. This page covers its latest market performance, valuation, price trends and company information.
$5.08B | |
$57.10 | |
$58.74 | |
$54.76 | |
$56.73 | |
1.00M | |
3.56M | |
-- | |
$93.61 | |
$22.31 | |
-- | |
2026-09-30 |
Liquidia Corporation (LQDA) last closed at $56.43 as of 2026-11-19 00:55:00, down 0.56% ($0.31) from the previous close of $56.73.
During the latest regular trading session, LQDA traded between $54.76 and $58.74, with a volume of 1.00M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Liquidia Corporation (LQDA) moved from $47.87 to $56.43, representing a gain of 17.88% ($8.56).
The stock traded between $45.08 and $59.50 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.51 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 47.8%
LQDA is currently trading at $56.43, placing it 47.8% of the way from its 52-week low of $22.31 to its 52-week high of $93.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 216 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Liquidia Corporation and LQDA stock.
HC Wainwright & Co. analyst Matthew Caufield assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $76.
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Liquidia Corporation (LQDA) reported Q3 2026 revenues of $225.3M, surging 314.6% year-over-year, with YUTREPIA sales reaching $222.7M, up 31% sequentially. The company achieved record October patient shipments and expanded its prescriber base to 1,300 despite temporary referral disruptions following a settlement with United Therapeutics. Management maintained a 94% gross margin and plans to provide 2027 revenue guidance in January.
Eligible investors can buy real shares of Liquidia Corporation (LQDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LQDA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LQDA shares and USD.
LQDA Shares to USD
1.00 LQDA shares = 56.427 USD
Calculations are estimates based on the latest available price and are for reference only.